Evogene (EVGN) Net Cash Flow (2013 - 2026)

Evogene has disclosed Net Cash Flow across 14 years of filings, most recently posting -$1.8 million for Q2 2026.

• In Q2 2026, Net Cash Flow fell 313.74% year-over-year to -$1.8 million; the TTM figure through Jun 2026 stood at -$9.3 million (down 1891.01% YoY), while the FY2025 annual figure was -$2.4 million, up 56.36% from the prior year.
• Net Cash Flow came in at -$1.8 million for Q2 2026 at Evogene, up from -$4.4 million in the prior quarter.
• In the past five years, Net Cash Flow ranged from a high of $7.3 million in Q4 2025 to a low of -$10.3 million in Q3 2025.
• Average Net Cash Flow over 5 years is -$1.7 million, with a median of -$2.4 million recorded in 2023.
• Year-over-year, Net Cash Flow soared 159.96% in 2022 and sank 518.63% in 2025.
• Over 5 years, Net Cash Flow stood at -$3.1 million in 2022, then sank by 117.58% to -$6.7 million in 2023, then soared by 159.94% to $4.0 million in 2024, then soared by 83.44% to $7.3 million in 2025, then sank by 125.08% to -$1.8 million in 2026.
• Per Business Quant data, the three most recent Net Cash Flow figures were -$1.8 million in Q2 2026, -$4.4 million in Q1 2026, and $7.3 million in Q4 2025.